XML 18 R3.htm IDEA: XBRL DOCUMENT v3.24.3
Consolidated Statements of Comprehensive Income - AUD ($)
 12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2022
Revenue      
License revenue $ 0 $ 0 $ 170,369
Other income      
Research material sales 119,089 191,721 84,018
Grant income 3,722,788 3,314,001 4,459,974
Net gain on foreign exchange 113,458 623,511 1,228,122
Net gain on fair value movement of warrants 0 131,896 591,070
Interest income 3,882,757 938,999 224,520
Miscellaneous 533 0 0
Total revenue and other income 7,838,625 5,200,128 6,758,073
Expenses      
Research & development and intellectual property expenses (41,546,724) (36,257,187) (31,341,576)
Corporate administrative expenses (8,852,615) (8,679,840) (7,210,123)
Finance costs (30,594) (20,401) (92,430)
Net Changes in fair value of convertible note liability (125,317) (139,048) (324,736)
Loss before income tax expense (42,716,625) (39,896,348) (32,210,792)
Income tax expense 0 0 (34) [1]
Loss after income tax expense for the year (42,716,625) (39,896,348) (32,210,826)
Other Comprehensive Income/(Loss)      
Exchange differences on the translation of foreign operations (1,421,191) 3,592,502 (922,327)
Other comprehensive income/(loss) for the year, net of tax (1,421,191) 3,592,502 (922,327)
Total comprehensive income/(loss) for the year (44,137,816) (36,303,846) (33,133,153)
Loss for the year is attributable to:      
Owners of Immutep Limited (42,716,625) (39,896,348) (32,210,826)
Total comprehensive loss for the year is attributable to:      
Owners of Immutep Limited $ (44,137,816) $ (36,303,846) $ (33,133,153)
Basic loss per share $ (0.0356) $ (0.0447) $ (0.0379)
Diluted loss per share $ (0.0356) $ (0.0447) $ (0.0379)
[1] Income tax expense relates to tax payable for the Immutep subsidiary in the United States.